{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=solanezumab", "query": { "intervention": "solanezumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=solanezumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T03:40:57.802Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04623242", "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Solanezumab", "type": "DRUG" }, { "name": "Matching Placebo (Gantenerumab)", "type": "DRUG" }, { "name": "Matching Placebo (Solanezumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 194, "start_date": "2012-12", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2022-09-22", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04623242" }, { "nct_id": "NCT02760602", "title": "A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Solanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 26, "start_date": "2016-06", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 98, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760602" }, { "nct_id": "NCT02614131", "title": "A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Alzheimer's Disease", "Mild Cognitive Impairment" ], "interventions": [ { "name": "LY2599666", "type": "DRUG" }, { "name": "Solanezumab", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 50, "start_date": "2015-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2020-06-17", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 3, "location_summary": "Glendale, California • Marlton, New Jersey • Salt Lake City, Utah", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02614131" }, { "nct_id": "NCT00329082", "title": "Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "LY2062430", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 25, "start_date": "2006-05", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2009-10-07", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329082" }, { "nct_id": "NCT00905372", "title": "Effect of LY2062430 on the Progression of Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "LY2062430", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 1000, "start_date": "2009-05", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-09-25", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 59, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tuscon, Arizona + 56 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tuscon", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carson", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00905372" }, { "nct_id": "NCT01148498", "title": "A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "solanezumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 55, "start_date": "2010-08", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-09-25", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148498" }, { "nct_id": "NCT02008357", "title": "Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cognition Disorders" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Solanezumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "65 Years to 85 Years" }, "enrollment_count": 1169, "start_date": "2014-02-28", "completion_date": "2023-06-08", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008357" }, { "nct_id": "NCT00904683", "title": "Effect of LY2062430 on the Progression of Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "LY2062430", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 1040, "start_date": "2009-05", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-12-13", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 16, "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00904683" }, { "nct_id": "NCT01760005", "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Solanezumab", "type": "DRUG" }, { "name": "Matching Placebo (Gantenerumab)", "type": "DRUG" }, { "name": "Matching Placebo (Solanezumab)", "type": "DRUG" }, { "name": "E2814", "type": "DRUG" }, { "name": "Lecanemab", "type": "DRUG" }, { "name": "Matching Placebo (E2814)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 490, "start_date": "2012-12", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 12, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760005" }, { "nct_id": "NCT01900665", "title": "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Solanezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 2129, "start_date": "2013-07", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-09-05T03:40:57.802Z", "location_count": 120, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 93 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01900665" } ] }